Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: A prospective-retrospective study

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 2, 2015, Pages 199-208

  Chong, C C N ^a   Wong, G L H ^a   Wong, V W S ^a   Ip, P C T ^a   Cheung, Y S ^a   Wong, J ^a   Lee, K F ^a   Lai, P B S ^a   Chan, H L Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; LIVER FUNCTION TEST; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS B; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84918532418     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13034     Document Type: Article

References (45)

1. Liaw YF, Sung JJ, Chow WC, et al,. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
2. Wong GL, Chan HL, Mak CW, et al,. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 2013; 58: 1537-47.
3. Matsumoto A, Tanaka E, Rokuhara A, et al,. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
4. Yuen MF, Seto WK, Chow DH, et al,. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007; 12: 1295-303.
5. Wong JS, Wong GL, Tsoi KK, et al,. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-12.
6. Miao RY, Zhao HT, Yang HY, et al,. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010; 16: 2931-42.
7. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
8. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update (vol 6, pg 531, 2012). Hep Intl 2012; 6: 809-10.
9. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
10. Liaw YF, Leung N, Guan R, Lau GK, Merican I,. Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18: 239-45.
11. Chan HL, Chui AK, Lau WY, et al,. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-7.
12. Lee KF, Chong CN, Wong J, Cheung YS, Wong J, Lai P,. Long-term results of laparoscopic hepatectomy versus open hepatectomy for hepatocellular carcinoma: a case-matched analysis. World J Surg Oct 2011; 35: 2268-74.
13. Strasberg SM,. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg 2005; 12: 351-5.
14. Chong CC, Lee KF, Ip PC, et al,. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? Surgeon 2012; 10: 260-6.
15. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
16. Edge SB,; American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.
17. Chao DT, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH,. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther 2014; 39: 349-58.
18. Enriquez AD, Campbell MS, Reddy KR,. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther 2007; 26: 383-91.
19. Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
20. Hosaka T, Suzuki F, Kobayashi M, et al,. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107.
21. Singal AK, Salameh H, Kuo YF, Fontana RJ,. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
22. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF,. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008; 103: 1663-73.
23. Koda M, Nagahara T, Matono T, et al,. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med 2009; 48: 11-7.
24. Kubo S, Tanaka H, Takemura S, et al,. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007; 37: 94-100.
25. Piao CY, Fujioka S, Iwasaki Y, et al,. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma-using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-24.
26. Shuqun C, Mengchao W, Han C, et al,. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogast-roenterology 2006; 53: 249-52.
27. Yoshida H, Yoshida H, Goto E, et al,. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hep Intl 2008; 2: 89-94.
28. Chan AC, Chok KS, Yuen WK, et al,. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg 2011; 146: 675-81.
29. Li N, Lai EC, Shi J, et al,. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol 2010; 17: 179-85.
30. Kuzuya T, Katano Y, Kumada T, et al,. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-35.
31. Yin J, Li N, Han Y, et al,. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol 2013; 31: 3647-55.
32. Kim WR, Gores GJ,. Recurrent hepatocellular carcinoma: it's the virus!. J Clin Oncol 2013; 31: 3621-2.
33. Huang L, Li J, Lau WY, et al,. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 158-64.
34. Jang JW, Choi JY, Bae SH, et al,. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-40.
35. Thia TJ, Lui HF, Ooi LL, et al,. A study into the risk of exacerbation of chronic hepatitis B after liver resection for hepatocellular carcinoma. J Gastrointest Surg 2007; 11: 612-8.
36. Kubo S, Hirohashi K, Tanaka H, et al,. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-24.
37. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M,. Immunosuppression following surgical and traumatic injury. Surg Today 2010; 40: 793-808.
38. Huang L, Li J, Yan J, et al,. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepatitis 2013; 20: 336-42.
39. Ko S, Nakajima Y, Kanehiro H, et al,. Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis. Ann Surg 1996; 224: 591-5.
40. Tarao K, Takemiya S, Tamai S, et al,. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79: 688-94.
41. Wong GL, Chan HL, Chan HY, et al,. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144: 933-44.
42. Wu CY, Chen YJ, Ho HJ, et al,. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. J Am Med Assoc 2012; 308: 1906-13.
43. Padhya KT, Marrero JA, Singal AG,. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2013; 29: 285-92.
44. Lau WY, Lai ECH, Lau SHY,. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 2009; 8: 124-33.
45. Fan ST, Mau Lo C, Poon RT, et al,. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-58.